Sitewide
VOICE trial indicates daily dosing of tenofovir gel ineffective
Arlington, VA – An independent review of the VOICE study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the Microbicide Trials Network, determined that tenofovir gel was no more effective than placebo gel in preventing HIV. The review found no safety concerns and the VOICE study will continue to evaluate the effectiveness of the oral Truvada tablet in preventing HIV in women. It is unknown at this time why tenofovir gel did not work in this particular trial. The study will need to be completed before data can be analyzed to determine whether adherence to a daily regimen was possibly a key factor.
Use of tenofovir gel was shown to be effective in reducing HIV and herpes infections in the CAPRISA 004 study, which tested a different dosing strategy where women were asked to use the gel before and after sex. The CONRAD-sponsored FACTS 001 trial, which is currently assessing the same dosing regimen as the CAPRISA 004 trial, is ongoing in South Africa.
"Tenofovir gel is still a promising new product for women," said CONRAD Executive Director Dr. Henry Gabelnick. "Despite the disappointment of this result, VOICE will contribute important safety data toward the possible licensure of tenofovir gel. We are pleased that USAID, the Bill & Melinda Gates Foundation, and the government of South Africa are supporting the FACTS study, which will serve to provide confirmatory results for regulatory approval."
Gilead Sciences licensed tenofovir royalty-free to CONRAD, who manufactured and supplied the gel for the CAPRISA 004, VOICE and FACTS 001 trials. CONRAD and the South African Government's Technology Innovation Agency (TIA) have a license agreement that grants TIA the rights to manufacture and distribute tenofovir gel in Africa, pending regulatory approval.
If FACTS 001 can confirm CAPRISA's positive results, these combined effectiveness data, along with VOICE's safety data on tenofovir gel, may enable the licensure of the first microbicide for women, and a powerful new tool for women to protect themselves from HIV and genital herpes.
Popular Today:
Similar Articles On This Topic:
- Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
- Trial finds tenofovir gel safe for daily use and most women adhered to study regimens
- NIH discontinues tenofovir vaginal gel in 'VOICE' HIV prevention study
- Tenofovir gel dropped from HIV prevention trial in women because it was not effective
- Tenofovir gel wins out in drug absorption study, but HIV prevention trials say differently
Science 2.0:
Recent Articles:
Create Your Own Releases:
Herpes is one of the most
Herpes is one of the most misunderstood std's out there. The simple truth is that 90% of the adult population has it but doesn't realize it. If you ever get a fever blister you have herpes. The only difference between mouth herpes and the other kind is simply where it's located. It's the same virus, resting at the back of your brain untill something triggers it and you get an outbreak. There is no difference in oral herpes and the other kind, just the location, and there is no cure for herpes, though drugs such as Valtrax can stop an ourbreak once you get one. Odds are these wrestlers already had the virus and why the big to do here is beyond me. You may know more about herpes on the dating and support site POZloving. Good luck to you all!
South African research
South African research agencies have issued several press releases related to the VOICE Trial.
For more information on the Data Safety and Monitoring Board's findings as well as press statements issued by research agencies engaged in microbicide research go to www.sanacws.org.za.
http://www.sanacws.org.za/en/announcements/view/pivotal-hiv-prevention-trial-for-women-in-africa-finds-that-use-o
http://www.sanacws.org.za/en/announcements/view/caprisa-statement-on-voice-trial
Post new comment